Q32 Bio Inc. cotiza a 8.74 USD y tiene una capitalización bursátil de $260M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 re…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.44 | $-0.54 | $4.58 | $-0.60 |
| Estimado | $-0.54 | $-0.68 | $-0.86 | $-1.19 |
| Sorpresa | +18.5% | +20.6% | +632.6% | +49.6% |
| Métrica | QTTB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | 31.4% | -38.6% | +70.1% |
| Net Margin | 55.5% | -33.6% | +89.1% |
| FCF Margin | -62.4% | -13.9% | -48.6% |
| ROE | 71.0% | -40.4% | +111.4% |
| ROA | 48.3% | -32.0% | +80.3% |
| Current Ratio | 4.85 | 2.84 | +2.01 |
| Debt / Equity | — | 0.28 | — |